A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9

advanced solid cancers, anti-drug conjugate (adc), bile duct cancer, ca19-9, colorectal cancer, endometrial cancer, gastric adenocarcinoma, gastroesophageal junction cancer, invasive urothelial carcinoma of the bladder and urinary tract, ovarian cancer, pancreatic ductal adenocarcinoma, interventional